Quest Diagnostics Incorporated

• DGX Stock Price change on Jan 13: +2.28%. Closed at 179.96 USD (NYSE). The gain was primarily driven by positive sentiment following the company's presentation at the J.P. Morgan Healthcare Conference, where it highlighted a strong long-term growth outlook and stable medical utilization trends.
• Technical Indicators: RSI (14) is at 34.11 (Neutral/Oversold territory); MACD is -2.52 (suggesting a potential "Buy" on momentum shift); 50-day SMA is 181.44 and 200-day SMA is 174.52. Technically, the stock is testing support near its 200-day moving average after a recent pullback; while short-term trends remain bearish, the proximity to long-term support and a low RSI suggests a potential rebound or stabilization phase.
• Quest Diagnostics highlighted its post-2025 outlook at a major healthcare conference, projecting a 4-5% revenue CAGR and 7-9% adjusted EPS CAGR, signaling long-term operational stability.
• The company went ex-dividend on January 13, 2026, for its quarterly payment of $0.80 per share, reinforcing its status as a reliable income stock for dividend investors.
• Quest Diagnostics announced it will present new data on its Haystack MRD® technology at the 2026 ASCO Gastrointestinal Cancers Symposium, focusing on advancements in cancer molecular residual disease testing.
• UnitedHealth Group faced scrutiny following a Senate report alleging aggressive diagnosis coding to inflate Medicare Advantage payouts, impacting sentiment across the healthcare services and insurance sectors.
• OpenAI expanded its footprint in the sector by acquiring a healthcare startup to unify lab results and provider data, highlighting the increasing integration of AI in diagnostic information services.

• DGX Stock Price 24h change: +0.86%. From 175.81 USD to 175.94 USD.
• From a technical perspective, the stock is in a "short-term bearish consolidation" phase. While the long-term trend remains relatively neutral to bullish (SMA 200 at ~177.50), the price is currently trading below its 20-day (177.78) and 50-day (181.11) moving averages, indicating immediate downward pressure. The RSI is neutral at 41.17, suggesting the stock is neither overbought nor oversold.
• Quest Diagnostics and Corewell Health finalized a joint venture on January 5, 2026, forming "Diagnostic Lab of Michigan" to expand laboratory service access in the region.
• The company declared a quarterly cash dividend of $0.80 per share, payable on January 28, 2026, to shareholders of record as of January 13, 2026.
• Quest Diagnostics announced it will release its fourth quarter and full-year 2025 financial results on February 10, 2026, before the market opens.
• A U.S. Senate investigation report released on January 12, 2026, alleged that UnitedHealth used aggressive risk-adjustment tactics to significantly boost Medicare Advantage payments.
• Eli Lilly partnered with Humana's CenterWell Pharmacy on January 12, 2026, to dispense obesity medications directly through employer-sponsored health programs, reflecting a shift in specialty drug distribution.